CDT Highlights Sarborg’s Application of Signature Intelligence and Quantum Computing Models to Mental Health
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 10, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today notes the announcement from Sarborg Limited regarding the successful application of its patented Signature Intelligence and quantum computing models to mental health and neuropsychiatric drug discovery.
Mental health represents a significant global healthcare opportunity, with more than 1 billion people globally1 living with a mental disorder and depression and anxiety alone estimated to cost the global economy approximately $1 trillion annually2. Sarborg has developed a proprietary database of neuropsychiatric disease signatures, including depression, bipolar disorder, anxiety and schizophrenia, and has successfully applied its Signature Intelligence and quantum computing models to identify potential relationships between disease signatures and therapeutic candidates.
CDT believes the application of Sarborg’s technology to neuropsychiatric drug discovery demonstrates the broader potential of its patented models across significant areas of unmet medical need. Sarborg is currently in discussions with pharmaceutical and biotechnology companies, academic institutions and research organisations regarding potential applications and strategic collaborations.
“We are pleased to see Sarborg successfully applying its patented Signature Intelligence and quantum computing models to the mental health sector,” said James Bligh, Chief Executive Officer of CDT Equity. “The ability to combine proprietary biological signatures with quantum computing has the potential to uncover new relationships and therapeutic opportunities within highly complex disease areas.”
CDT holds 1,290 shares in Sarborg, representing 22.7% of the issued share capital. Sarborg’s latest capital raise was at $125,000 per share, implying a fully diluted valuation of approximately $709 million.
A copy of Sarborg’s full announcement is available at: Sarborg Successfully Applies Patented Signature and Quantum Computing Models to Mental Health and Neuropsychiatric Drug Discovery & www.sarborg.com/news.
1 https://www.who.int/news/item/02-09-2025-over-a-billion-people-living-with-mental-health-conditions-services-require-urgent-scale-up?utm_source=chatgpt.com
2 https://www.who.int/news/item/13-04-2016-investing-in-treatment-for-depression-and-anxiety-leads-to-fourfold-return?utm_source=chatgpt.com
About CDT Equity Inc.
CDT Equity Inc. (NASDAQ: CDT) is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. Originally established as Conduit Pharmaceuticals, the company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. Looking ahead, CDT are committed to creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding CDT's future results of operations and financial position, CDT's business strategy, prospective product candidates, product approvals, research and development cost timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated studies and business endeavors with third parties, and future results of current and anticipated product candidates, are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to; the effect that the reverse stock split may have on the price of the Company’s common stock; the ability or inability to maintain the listing of CDT's securities on Nasdaq; the ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by, among other things, competition; the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that CDT's product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all; changes in applicable laws or regulations; the possibility that CDT may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties identified in other filings made by CDT with the U.S. Securities and Exchange Commission. Moreover, CDT operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond CDT's control, you should not rely on these forward-looking statements as predictions of future events.
Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, CDT assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. CDT gives no assurance that it will achieve its expectations.
Investors
CDT Equity Inc.
Info@cdtequity.com
